Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural Bevacizumab for Malignant Pleural Effusion in Breast Cancer
NCT02250118Phase 1Terminated
- Sponsor
- Institut Curie
- Start
- Dec 2014
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab in malignant pleural effusion (MPE), sponsored by Institut Curie. Primary endpoint: Maximum Tolerated Dose at 90 days. Started Dec 2014; status: terminated.
02
Drugs
bevacizumab
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT02250118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250118.